undamentalytics Newsletter
Sign in

Verastem, Inc. (VSTM) stock

Add to watchlist

Add holding +

NASDAQ: VSTM Nasdaq Biotechnology Next results ~November 5, 2026

Verastem, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Verastem, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: cash-flow, stock-pay or share-count figures missing or out of date. We'll show the comparison once resolved.

Verastem, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 6 selling0 purchases and 33 sales by directors and officers, last 12 monthsInsider trades
  • Funds102 adding, 63 cuttingOf 35 active managers that changed their stake, 19 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Verastem files

Where Verastem stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $88m, up 26.4% on a year earlier, slower than the 56.0% growth a quarter earlier. Free-cash-flow margin fell to -185.3% from -12.3% a year earlier. Operating margin widened to -182.6% from -2218.9%. It passes 2 of our 3 financial-health checks.

Our model value for Verastem is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 31% in the quarter to 2026-06-30, the 4th beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 26.4% over the last 12 months.
  • Margins widening. Operating margin is up 181.6 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Growth slowing. The growth rate is 29.5 points lower than a quarter earlier.
  • Loss-making. Operating margin is -182.6%: costs exceed revenue.
  • Burning cash. Free cash flow was -185.3% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 33.4% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 76% and a beta of 1.0 against the S&P 500.
  • Heavily shorted. 14.2% of the shares available to trade are sold short (3.8 days of average volume to cover).

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.31 against an average estimate of -$0.45: beat by 30.6%
Revenue
$40m, up 1775.4% on a year earlier
Share reaction
+23.9% in the first session after the results on October 14, 2026, against -0.8% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.44

Verastem's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.9%
  • 1 week-3.3%
  • 1 month+26.9%
  • This year+24.2%
  • 1 year-1.3%
  • 5 years-71.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$87.5M
Operating margin
-182.6%
Net margin
-231.6%
EPS (TTM, diluted)
$-2.33

Cash

Free cash flow (TTM)
-$162M
FCF margin
-185.3%
Stock pay % of revenue
11.1%

Earnings

Last results
October 14, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results
  3. Agreement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Verastem, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: cash-flow, stock-pay or share-count figures missing or out of date.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Verastem, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.04 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$1.2 ~$2.6–$8.9 Left out: out of range vs price (0.12x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Verastem, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2018201920202021202220242025Now
Share price$40.32$16.08$25.56$24.60$4.80$5.17$7.72$9.59
Market value$233.2bn$100.0bn$327m$715m$155m$369m$535m$835m
+ Net debt (− = net cash)−$35m$25m−$49m−$21m−$50m−$48m−$129m−$62m
Enterprise value$233.1bn$100.1bn$278m$694m$105m$321m$406m$773m
Multiples
Price / sales n/mn/m3.7xn/m59.7x36.9x17.3x9.5x
Price / earnings ————————
Price / free cash flow ————————
EV / EBITDA ————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

28 /100

Weak moat

How hard Verastem's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -69.9% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -486.2%; its worst year was -2218.9%.

  • Discipline 10 / 20

    The diluted share count fell 94.4% over five years; stock-based pay has been a median 28.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (33 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $26m and EPS of −$0.44 (range −$0.44 to −$0.44) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.80 +23% $111m +260%
Next −$1.22 +32% $159m +43%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +15.6% on 90 days ago. In the last 30 days, 1 analyst raised Verastem, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Verastem, Inc., last 90 days
−$2.00 −$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.56 Current fiscal year, 60 days ago: −$1.80 Current fiscal year, 30 days ago: −$1.80 Current fiscal year, 7 days ago: −$1.80 Current fiscal year, Now: −$1.80 −$1.80 Next fiscal year, 90 days ago: −$1.16 Next fiscal year, 60 days ago: −$0.75 Next fiscal year, 30 days ago: −$0.75 Next fiscal year, 7 days ago: −$1.22 Next fiscal year, Now: −$1.22 −$1.22

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.56−$1.16
60 days ago −$1.80−$0.75
30 days ago −$1.80−$0.75
7 days ago −$1.80−$1.22
Now −$1.80−$1.22

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.45 −$0.31 +30.6%
Mar 2026 −$0.47 −$0.43 +7.9%
Dec 2025 −$0.50 −$0.46 +7.5%
Sept 2025 −$0.61 −$0.54 +11.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

10 analysts, Oct 2026
Buy10100%
Hold00%
Sell00%

Monthly trend

  1. Oct 20261910
  2. Sep 20261910
  3. Aug 2026189
  4. Jul 2026189

Counts of recommendations published by analysts covering Verastem, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
14.2%
of tradable shares
Days to cover
3.77
at average volume
Short interest, 1 month
−5%
to October 15, 2026
Held by institutions
83%
of shares
Held by insiders
0.8%
of shares
Employees
102
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
VSTM−4%−81%+70%−37%+49%+24%
Industry peers (median)−36%−56%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
VSTM58%33%42%42%67%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
VSTM−58%−86%−52%−84%−51%−56%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 98% from August 30, 2018 to August 5, 2024. Getting back needed a 5338% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.45 – $10.64
From 52-week high
−9.9%
vs 50-day average
+16.8%
vs 200-day average
+55.1%
Volatility (1 year)
76%
Beta vs S&P 500
1.02

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±19.9%
After a week
6 up, 6 down
typical move ±21.2%
After a month
7 up, 4 down
typical move ±20.3%
Results releasedNext dayS&P 500 next day5 days21 days
October 14, 2026 +23.9% −0.8% +23.6% —
August 6, 2026 +14.8% +0.5% +13.6% +39.7%
February 4, 2026 −0.3% −1.7% +0.6% +1.3%
November 4, 2025 −17.6% −0.8% −14.6% +7.1%
January 13, 2025 −12.0% +0.3% −5.9% +6.1%
February 2, 2023 +10.9% +0.4% −3.1% −26.6%
August 8, 2022 +1.7% −0.5% +15.1% +2.5%
March 28, 2022 +26.9% +2.0% +28.6% +26.9%
August 10, 2020 −2.0% −0.5% −0.7% −20.3%
April 27, 2020 −54.5% +1.0% −53.5% −57.6%
February 28, 2020 +56.0% +3.9% +77.0% +34.0%
October 29, 2019 −18.8% +0.3% −18.0% −0.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Verastem, Inc.
$0 $50M $100M FY20 Q3 FY21 Q2 FY22 Q1 FY26 Q2 Revenue (TTM), FY20 Q3: $91.6M Revenue (TTM), FY20 Q4: $88.5M Revenue (TTM), FY21 Q1: $84.5M Revenue (TTM), FY21 Q2: $80.7M Revenue (TTM), FY21 Q3: $2M Revenue (TTM), FY21 Q4: $2.1M Revenue (TTM), FY22 Q1: $3.6M Revenue (TTM), FY22 Q2: $3.1M Revenue (TTM), FY22 Q3: $3.1M Revenue (TTM), FY22 Q4: $2.6M Revenue (TTM), FY26 Q1: $49.6M Revenue (TTM), FY26 Q2: $87.5M $87.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY20 Q3 $91.6M
FY20 Q4 $88.5M
FY21 Q1 $84.5M
FY21 Q2 $80.7M
FY21 Q3 $2M
FY21 Q4 $2.1M
FY22 Q1 $3.6M
FY22 Q2 $3.1M
FY22 Q3 $3.1M
FY22 Q4 $2.6M
FY26 Q1 $49.6M
FY26 Q2 $87.5M
Revenue growth, TTM YoY Verastem, Inc.
-200% 0% 200% 400% 600% FY20 Q1 FY20 Q4 FY21 Q3 FY22 Q4 Revenue growth, TTM YoY, FY20 Q1: 13.3% Revenue growth, TTM YoY, FY20 Q2: 91.0% Revenue growth, TTM YoY, FY20 Q3: 508.9% Revenue growth, TTM YoY, FY20 Q4: 407.1% Revenue growth, TTM YoY, FY21 Q1: 305.3% Revenue growth, TTM YoY, FY21 Q2: 266.4% Revenue growth, TTM YoY, FY21 Q3: -97.8% Revenue growth, TTM YoY, FY21 Q4: -97.7% Revenue growth, TTM YoY, FY22 Q1: -95.7% Revenue growth, TTM YoY, FY22 Q2: -96.1% Revenue growth, TTM YoY, FY22 Q3: 56.0% Revenue growth, TTM YoY, FY22 Q4: 26.4% 26.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY20 Q1 13.3%
FY20 Q2 91.0%
FY20 Q3 508.9%
FY20 Q4 407.1%
FY21 Q1 305.3%
FY21 Q2 266.4%
FY21 Q3 -97.8%
FY21 Q4 -97.7%
FY22 Q1 -95.7%
FY22 Q2 -96.1%
FY22 Q3 56.0%
FY22 Q4 26.4%
Operating margin (TTM) Verastem, Inc.
-4000% -3000% -2000% -1000% 0% FY20 Q3 FY21 Q2 FY22 Q1 FY26 Q2 Operating margin (TTM), FY20 Q3: -71.9% Operating margin (TTM), FY20 Q4: -55.8% Operating margin (TTM), FY21 Q1: -43.9% Operating margin (TTM), FY21 Q2: -39.4% Operating margin (TTM), FY21 Q3: -3061.2% Operating margin (TTM), FY21 Q4: -2991.2% Operating margin (TTM), FY22 Q1: -1764.5% Operating margin (TTM), FY22 Q2: -2218.9% Operating margin (TTM), FY22 Q3: -2311.4% Operating margin (TTM), FY22 Q4: -2809.6% Operating margin (TTM), FY26 Q1: -344.6% Operating margin (TTM), FY26 Q2: -182.6% -182.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY20 Q3 -71.9%
FY20 Q4 -55.8%
FY21 Q1 -43.9%
FY21 Q2 -39.4%
FY21 Q3 -3061.2%
FY21 Q4 -2991.2%
FY22 Q1 -1764.5%
FY22 Q2 -2218.9%
FY22 Q3 -2311.4%
FY22 Q4 -2809.6%
FY26 Q1 -344.6%
FY26 Q2 -182.6%
FCF margin (TTM) Verastem, Inc.
-4000% -3000% -2000% -1000% 0% FY21 Q2 FY21 Q3 FY21 Q4 FY26 Q1 FY26 Q2 FCF margin (TTM), FY21 Q2: -12.3% FCF margin (TTM), FY21 Q3: -3250.6% FCF margin (TTM), FY21 Q4: -2615.6% FCF margin (TTM), FY26 Q1: -304.4% FCF margin (TTM), FY26 Q2: -185.3% -185.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY21 Q2 -12.3%
FY21 Q3 -3250.6%
FY21 Q4 -2615.6%
FY26 Q1 -304.4%
FY26 Q2 -185.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 27 17 89 2 3 10 31 88
Gross profit 27 — — — — — — —
EBITDA −94 −132 −49 −61 −73 −115 −170 —
Operating income −95 −132 −49 −61 −73 −115 −170 −160
Net income −72 −149 −68 −71 −74 −131 −209 −203
Diluted EPS −$0.02 −$0.02 −$0.01 −$2.45 −$2.29 −$1.83 −$3.02 −$2.33
Growth (year on year)
Revenue — −34.7% +407.1% −97.7% +26.4% +285.2% +209.1% —
Margins
Gross margin 99.4% — — — — — — —
EBITDA margin −351.0% −755.7% −55.2% <−999% <−999% <−999% −550.2% —
Operating margin −354.8% −758.1% −55.8% <−999% <−999% <−999% −550.3% −182.6%
Net margin −271.1% −854.8% −76.5% <−999% <−999% <−999% −677.6% −231.6%
Free-cash-flow margin −284.5% −793.6% −37.9% <−999% — <−999% −444.8% −185.3%
Cash flow
Cash from operations −75 −139 −34 −54 −64 −105 −138 −162
Capital spending 2 0 0 0 — 0 0 0
Free cash flow −76 −139 −34 −54 — −105 −138 −162
Stock-based pay 7 9 8 8 6 7 9 10
Free cash flow after stock pay −83 −147 −42 −61 — −112 −147 −172
Balance sheet
Cash 130 44 68 21 75 89 205 136
Total debt 95 69 19 0 25 41 76 74
Net debt (negative = net cash) −35 25 −49 −21 −50 −48 −129 −62
Diluted shares 5,783m 6,221m 13m 29m 32m 71m 69m 87m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $207m
Short-term assets $176mLonger-term assets $30m
What it owes, and who funded it · $207m
Short-term liabilities $78mLonger-term liabilities $78mShareholders' equity $50m
  • Short-term assets cover short-term liabilities $176m of assets due within a year against $78m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $176m short-term assets against $78m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$160m against $1m of interest.

From Verastem, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
160.2%
of revenue
Sales & admin spending
108.7%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated VSTM BCYC FDMT PLX AAPG ADCT Median
Revenue, last 12 months $88m $84m $92m $81m $80m $80m $56m
Revenue growth, last 12 months 26.4% 194.7% >999% 30.1% −41.4% 3.0% 12.6%
Revenue growth, 3-year average 58.4% 49.8% 242.8% 6.1% — — 13.7%
Revenue growth, latest quarter >999% 190.2% >999% 27.1% — 2.2% 10.2%
Gross margin — — — 69.2% 91.5% — 82.9%
Operating margin −182.6% −189.4% −214.2% 28.9% — −125.1% −189.4%
Operating margin, 3-year average −813.6% −581.7% <−999% 1.1% — −171.7% −363.5%
Net margin −231.6% −169.8% −194.7% 23.5% −216.5% −121.8% −169.8%
Cash from operations / revenue −185.3% −209.7% −169.6% 12.3% −204.5% −128.5% −168.0%
Free-cash-flow margin −185.3% −211.9% −169.6% 9.5% −209.3% −128.5% −162.4%
Free-cash-flow margin, 3-year average — −539.0% <−999% −2.3% — −171.3% −310.0%
Stock pay / revenue 11.1% 36.4% 22.2% 2.4% 3.6% 12.2% 20.0%
Change in share count 33.4% 0.6% 15.9% −4.1% 17.9% 38.3% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Operating margin Profitability -182.6% -189.4% 86 of 175
Net margin Profitability -231.6% -157.3% 100 of 180
Free-cash-flow margin Cash generation -185.3% -145.4% 96 of 176
Stock pay as % of revenue Cash generation 11.1% 19.2% 65 of 179

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$378M
Institutions reporting
158
Shares held vs prior quarter
▲ 21.5%
Positions opened / closed
33 / 26

Top buyers and sellers, Q2 2026: 102 institutions bought and 63 sold ; the biggest buyer was Nantahala Capital Management, LLC (+3.6M shares) and the biggest seller Citadel Advisors LLC (−2.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $35.1M 9.2M 9.3% ▲ 48.4%
Nantahala Capital Management, LLC $27.4M 7.2M 7.2% ▲ 100.0%
Armistice Capital, LLC $26.8M 7.0M 7.1% ▲ 53.0%
RTW Investments, LP $25.3M 6.6M 6.7% ▲ 0.9%
Deep Track Capital, LP $21.9M 5.7M 5.8% 0.0%
State Street Corp $19.6M 5.1M 5.2% ▲ 46.0%
Rosalind Advisors, Inc. $15.2M 4.0M 4.0% ▲ 86.4%
Vanguard Capital Management LLC $14.7M 3.9M 3.9% ▲ 15.9%
Stonepine Capital Management, LLC $12.8M 3.3M 3.4% ▲ 1.4%
Vanguard Portfolio Management LLC $12.5M 3.3M 3.3% ▲ 331.6%
Foresite Capital Management Vi LLC $12M 3.1M 3.2% 0.0%
Goldman Sachs Group Inc $10.4M 2.7M 2.8% ▲ 83.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Verastem, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $1.1M 33 trades by 6 insiders · 100% under pre-set plans
Net ▼ $1.1M net selling
Insider Date Trade Shares Price Value
Calkins Daniel Chief Financial Officer October 1, 2026 Sell pre-set plan 2,566 $8.00 $20,528
Paterson Dan President and CEO October 1, 2026 Sell pre-set plan 44,121 $8.00 $352,968
Calkins Daniel Chief Financial Officer September 21, 2026 Sell pre-set plan 55 $7.70 $424
Paterson Dan President and CEO August 3, 2026 Sell pre-set plan 1,302 $5.81 $7,565
Calkins Daniel Chief Financial Officer June 22, 2026 Sell pre-set plan 57 $4.13 $235
Calkins Daniel Chief Financial Officer June 22, 2026 Sell pre-set plan 4,032 $4.18 $16,854
Paterson Dan President and CEO June 22, 2026 Sell pre-set plan 20,871 $4.18 $87,241
Paterson Dan President and CEO May 4, 2026 Sell pre-set plan 806 $5.82 $4,691
Paterson Dan President and CEO February 4, 2026 Sell pre-set plan 970 $6.69 $6,489
Calkins Daniel Chief Financial Officer January 12, 2026 Sell pre-set plan 5,039 $7.16 $36,079
Paterson Dan President and CEO January 12, 2026 Sell pre-set plan 10,321 $7.16 $73,898
Calkins Daniel Chief Financial Officer December 24, 2025 Sell pre-set plan 80 $7.86 $629

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • October 14, 2026
  • August 6, 2026
  • February 4, 2026
  • November 4, 2025
  • January 13, 2025
  • February 2, 2023

Recent SEC filings

Data status

When each part of this page on Verastem, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Verastem, Inc. in brief

What does Verastem, Inc. do?
Verastem, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Verastem, Inc.'s stock ticker?
Verastem, Inc. trades under the ticker VSTM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Verastem, Inc.'s free cash flow?
Verastem, Inc.'s free-cash-flow margin is -185.3% of revenue over the trailing twelve months, ranking 96 of the 176 biotechnology companies we cover.
Who are Verastem, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Nantahala Capital Management, LLC and Armistice Capital, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Verastem, Inc.'s market cap?
On November 2, 2026, Verastem, Inc.'s market capitalisation was about $835M and net debt of -$62.4M. Market figures come from third-party market data and may be delayed.
Who are Verastem, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Verastem, Inc. are Bicycle Therapeutics PLC, 4d Molecular Therapeutics, Inc., Protalix Biotherapeutics, Inc., Ascentage Pharma Group International and ADC Therapeutics SA. The side-by-side comparison below sets their revenue, margins and growth against Verastem, Inc.'s.
Are insiders buying or selling Verastem, Inc. stock?
Over the last 12 months, Verastem, Inc.'s directors and officers reported 0 open-market purchases and 33 sales on Form 4. The insider trading page charts every trade.
When is Verastem, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Verastem, Inc. announces its own schedule.